KAZIA THERAPEUTICS ANNOUNCES PRECLINICAL DATA PRESENTED AT AACR CONFERENCE BY JOHNS HOPKINS UNIVERSITY SHOWING ACTIVITY OF PAXALISIB IN PAEDIATRIC BRAIN TUMOURSPRNewsWire • 04/08/22
TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCERPRNewsWire • 04/08/22
KAZIA TO PRESENT AT UPCOMING INVESTOR CONFERENCE AND AACR ANNUAL SCIENTIFIC MEETINGPRNewsWire • 03/21/22
PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVESTIGATING PAXALISIB IN COMBINATION WITH METFORMIN AND A KETOGENIC DIET ENROLLS FIRST PATIENTPRNewsWire • 02/28/22
KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCEPRNewsWire • 01/25/22
Kazia Therapeutics appoints US-based CFO to assist global market expansionProactive Investors • 12/12/21
Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed GlioblastomaPRNewsWire • 12/04/21
Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma PatientsBenzinga • 12/03/21
Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares upProactive Investors • 12/02/21
Kazia Therapeutics expands further in North America with Toronto glioblastoma studyProactive Investors • 11/29/21
Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMOProactive Investors • 11/15/21
Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolledProactive Investors • 11/10/21
Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapyProactive Investors • 11/04/21
Kazia Therapeutics gets boost with ‘buy' call from Maxim Group and valuation upgrade from EdisonProactive Investors • 10/28/21
Kazia Therapeutics' paxalisib program data garners increased target share price of A$2.83 from EdisonProactive Investors • 10/14/21
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/10/21